Press releases

LinKinVax has the trust of world-class partners and investors.

Our last Press releases

LinKinVax and Gustave Roussy announced first patient dosedin Phase I/IIa clinical study on HPV.DCVax in HPV-positiveoropharyngeal cancer

LinKinVax completes first batch production of “pancov”,its next generation multi-variant vaccine against covid and other coronaviruses

LinKinVax introduces its Scientific Advisory
Board with the appointment of three leading
experts in immunology and epidemiology

LinKinVax welcomes interim results of the ANRS
VRI06 Phase I trial evaluating a novel HIV vaccine

LinKinVax and Gustave Roussy collaborate to conduct a Phase I/IIa HPV.DCVax clinical trial for the treatment of patients with human papillomavirus (HPV) associated oropharyngeal cancer

LinKinvax just completed a new round of financing, initiated in 2022

Accelerating the production of more effective prophylactic or therapeutic vaccines and adapting them to emerging or rapidly mutating pathogens is a major public health challenge.

LinKinVax puts together a highly experienced team from the world of biopharmaceuticals to lead the clinical development and upscaling of its vaccine platform

LinKinVax appoints Dr Jiong Ma as independent board member